Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093093 · ClinicalTrials.gov registry record · Phase 3
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
NCT00093093 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 900 participants.
The verdict
NCT00093093, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis C patients who have never before received treatment.
Interventions
- DRUG Ribavirin
- DRUG Viramidine
- DRUG pegylated interferon alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2004-06 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093093
The ClinicalTrials.gov registry entry for NCT00093093 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT00093093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093093 about?
NCT00093093 is a clinical study titled "Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive". The purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis C patients who have never before received treatment.
What is the current status of trial NCT00093093?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2004-06. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00093093?
The interventions under investigation include: Ribavirin (DRUG), Viramidine (DRUG), pegylated interferon alfa-2a (DRUG).
Who is sponsoring clinical trial NCT00093093?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.